News

Take a look at the stories that stood out as pillars of progress and success in hematology gene and cell therapy development in 2023.

Review top news and interview highlights from the week ending December 22, 2023.

uniQure plans to initiate regulatory discussions in the US and Europe in the first quarter of 2024.

The company characterized the meeting as “productive”.

The associate professor at Fred Hutch Cancer Center discussed new data on the CD20-targeting CAR he presented at ASH 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Throughout 2023, interest in the application of CAR-T and other cell therapies to B-cell-driven autoimmune disease skyrocketed, with a multitude of clinical trials being initiated by various companies.

Data from an analysis of patients from the BEYOND study were presented at ASH 2023.

The commissioner of food and drugs at the FDA discussed the year's approvals and what may be coming on the horizon in the realm of advanced therapeutics.

The chief of hematology at Children’s Hospital of Philadelphia discussed the updated results she presented at ASH’s 2023 conference.

December is HIV/AIDs Awareness Month and CGTLive is taking a look at Excision's first-in-human CRISPR therapy trial for people with HIV-1.

The medical Director and interim co-Chief Medical Officer at Seattle Children's Therapeutics discussed possible research to move forward with CD19 T-APCs for patients with B-ALL.

Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital, also gave his thoughts on the recent FDA approval of Vertex and CRISPR’s exa-cel for sickle cell disease.

The professor of hematology at University of Lille and chair of LYSA also discussed what the group will be focusing on in 2024.

Exa-cel was recently approved for treating sickle cell disease under the name Casgevy.

The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed the need for research into how CAR T-cells act differently between sexes.

An analysis of participants from GENEr8-1 who had low transgene-derived Factor VIII expression was presented at ASH 2023.

Review top news and interview highlights from the week ending December 15, 2023.

The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed new data from CLIMB-121 presented at ASH 2023 supporting Casgevy's approval.

Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital discussed PRO data on Vertex and CRISPR’s gene-edited cell therapy for sickle cell disease.

The hematologist at the University of Navarra discussed updated data from the phase KarMMa-3 trial.

Rabi Hanna, MD, presented updated data from the RUBY and EdiThal trials at ASH 2023.

The chief medical officer of Orca Bio discussed some trends he was excited about at ASH’s 2023 conference.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chief hematology/oncology fellow at University of Chicago discussed new data from the ROCCA collaborative study presented at ASH 2023.

Marcela Maus, MD, PhD, Associate Professor of Medicine at Harvard Medical School discussed innovative new research in the field and in her own lab.

A pooled analysis of the ALLCAR19 and FELIX trials including patients with R/R B-ALL, B-CLL, and B-NHL were presented at ASH 2023.

The hematologist and cell therapist from the University of Miami Sylvester Comprehensive Cancer Center spoke about long-term outcome data he presented at ASH’s 2023 conference.